IDH2 and cancer: Examples include mutations of isocitrate dehydrogenase (IDH) that lead to an increased release of the side product d-2-hydroxyglutarate in cancer (IDH1 and IDH2), or in d-2-hydroglutaric aciduria (IDH2) [46, 47•], and TPI where pathogenic mutations have been associated with the production of methylglyoxal [36].